质量指标占比

研究类文章占比OA被引用占比撤稿占比出版后修正文章占比
93.07%99.77%0%0%

相关指数

{{chartTitle}}

影响因子

年发文量

自引率

最新IF值预测
预测IF值算法
根据标准的SCI影响因子计算公式,以2022年为例,预测IF(2022)=A/B,其中,A为该期刊2020年至2021年所有文章在2022年中被引用的次数;B为该期刊2020年至2021年所有文章的总数。预测的实时影响因子数据在全年中逐步接近真实IF数据,上半年的预测数据通常接近于6月底正式发布的数据,而下半年的实时影响因子则会从大约50%开始逐渐趋近于最终的IF值。(考虑数据入库延迟,可以根据当前月份占全年的比例来大致估计最终的IF值,且估算时可适当上调。)

0.0000数据截止 2025-6-20 日
86560人已查看 《Cell Reports Medicine》 期刊2026最新IF预测值

预警说明 查看说明

时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
2026年预警名单预测
无异常数据 期刊预警概率很低
结果仅供参考
*来源:中科院《 国际期刊预警名单》

中科院分区 查看说明

版本大类学科小类学科Top期刊综述期刊
2026年3月发布
(新锐分区)
医学1区
CELL BIOLOGY 细胞生物学1区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验1区
N/A
2025年3月升级版
医学1区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验1区
CELL BIOLOGY 细胞生物学2区
2023年12月旧的升级版
医学1区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验1区
CELL BIOLOGY 细胞生物学2区

JCR分区

WOS分区等级:1区
版本按学科分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
CELL BIOLOGYQ1
MEDICINE, RESEARCH & EXPERIMENTALQ1

CiteScore 查看说明

CiteScoreSJRSNIP学科分区排名
14.60
4.028
1.803
大类:Medicine
小类:General Medicine
Q122 / 668
大类:Medicine
小类:General Biochemistry, Genetics and Molecular Biology
Q117 / 225

期刊介绍

Cell Reports Medicine is a premium open-access journal from Cell Press publishing cutting-edge research in translational and clinical biomedical sciences that inform and influence human health and medicine. The content published in Cell Reports Medicine reaches a broad range of scientists and clinicians across the spectrum of medical disciplines, ensuring that your work will be both visible and accessible. The journal publishes original research that ranges from exciting concepts in human biology, health, and disease to all phases of clinical work. We encourage submissions featuring innovative ideas that open up new directions in clinical research and practice, as well as studies that provide critical information that enriches our understanding of current standards of care in diagnosis, treatment, and prognosis. This includes, but is not limited to, translational studies, clinical trials in all areas of medicine including long-term trial follow-ups as well as work in genomics, biomarker discovery, and developments in technology that contribute to diagnostics, treatment, and healthcare. Studies based on vertebrate model organisms also fall within the scope of the journal, provided that the results are directly relevant to human health and disease. Like our sister journal Cell Reports, we will consider impactful, single-point papers called reports, in addition to longer articles. Large datasets, techniques, and tools for the community can also be considered under the article format. We will also publish reviews covering recent literature in emerging and active fields. The professional in-house scientific editors at Cell Reports Medicine work closely with authors, reviewers, and the journal's editorial board to ensure exemplary editorial process, fair and robust peer review, and rapid dissemination and communication of your research.
-
年发文量375
国人发稿量119
国人发文占比31.8%
自引率0.9%
平均录取率32.34%数据非官方,来自网友分享经验
平均审稿周期平均17周数据非官方,来自网友分享经验
版面费-
偏重研究方向Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
期刊官网https://www.cell.com/cell-reports-medicine
投稿链接https://www.editorialmanager.com/cr-medicine

期刊高被引文献

已经到底了~
鹿粉61230
2025-08-18 14:59:37
年度发文量375篇,竞争不小。我突出研究创新,很快被认可。适合有创新成果、想在高区发表的科研人。
鹿粉52124
2025-07-02 15:44:02
这本OA期刊虽有成本,但影响因子10.6,中科院医学1区、JCR分区Q1,花点钱换高认可度,我觉得值。
鹿粉74739
2025-01-04 08:13:41
我本担心语言不过关,结果发现友好度高。国人发文占比31.80%,编辑和审稿人重内容,语言打磨下就没问题。
已经到底了~